Oryzon Genomics Company Top Insiders

ORYZF Stock  USD 3.36  0.00  0.00%   
Oryzon Genomics employs about 43 people. The company is managed by 10 executives with a total tenure of roughly 101 years, averaging almost 10.0 years of service per executive, having 4.3 employees per reported executive. Examination of Oryzon Genomics' management performance can provide insight into the company performance.
Saikat Nandi  Insider
Global Officer
Emili Cortada  Insider
Chief Officer
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oryzon Genomics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Oryzon Genomics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0419) % which means that it has lost $0.0419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0685) %, meaning that it generated substantial loss on money invested by shareholders. Oryzon Genomics' management efficiency ratios could be used to measure how well Oryzon Genomics manages its routine affairs as well as how well it operates its assets and liabilities.

Oryzon Genomics Workforce Comparison

Oryzon Genomics SA is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 86,918. Oryzon Genomics adds roughly 43.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.33) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.72.

Oryzon Genomics SA Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Oryzon Genomics SA Price Series Summation is a cross summation of Oryzon Genomics price series and its benchmark/peer.

Oryzon Genomics Notable Stakeholders

An Oryzon Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oryzon Genomics often face trade-offs trying to please all of them. Oryzon Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oryzon Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Saikat NandiGlobal OfficerProfile
Emili CortadaChief OfficerProfile
Enric CondominesCOO OperationsProfile
Xavier RiberaHead ComplianceProfile
Michael RopackiChief CNSProfile
Jordi PeyChief OfficerProfile
Sonia BezonChief OperationsProfile
Ana LimonSr AffairsProfile
Carlos ArjolChairman, CoFounderProfile
Neus BernadoChief OfficerProfile

About Oryzon Genomics Management Performance

The success or failure of an entity such as Oryzon Genomics SA often depends on how effective the management is. Oryzon Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oryzon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oryzon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. The company was founded in 2000 and is based in Cornell de Llobregat, Spain. Oryzon Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 43 people.

Oryzon Genomics Workforce Analysis

Traditionally, organizations such as Oryzon Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oryzon Genomics within its industry.

Oryzon Genomics Manpower Efficiency

Return on Oryzon Genomics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee109K
Net Loss Per Executive468.7K

Complementary Tools for Oryzon Pink Sheet analysis

When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.